Food, Drugs, Healthcare, Life Sciences

Women with BRCA1 or BRCA2 gene mutations depend on enhanced breast screening for early detection, but administrative gaps in the screening pathway can occur. This comprehensive guide empowers BRCA carriers with practical strategies to monitor their screening schedule, ask the right questions of healthcare providers, and confidently navigate potential administrative issues that could interrupt their care.

Belgium's federal Chamber of Representatives has adopted a comprehensive bill introducing significant changes to pharmaceutical reimbursement procedures, including simplified approval tracks, new combination therapy rules, and an 80 million EUR annual industry contribution. The legislation also addresses drug unavailability issues and postpones certain 2024 reforms until 2028, fundamentally reshaping the financial and operational landscape for pharmaceutical companies operating in Belgium.

European regulators are accelerating AI governance frameworks while balancing innovation with patient safety in digital health. The European Commission has published voluntary codes for AI-generated content marking and appointed expert bodies to enforce the AI Act, while the UK's MHRA launches regulatory sandboxes to test AI tools in medicines development and the ICO establishes comprehensive guidance for AI-powered healthcare technologies.